Home Articles List Article Information
Research in Oncology
Journal Archive
Volume Volume 21 (2025)
Volume Volume 20 (2024)
Volume Volume 19 (2023)
Volume Volume 18 (2022)
Volume Volume 17 (2021)
Volume Volume 16 (2020)
Volume Volume 15 (2019)
Volume Volume 14 (2018)
Volume Volume 13 (2017)
Volume Volume 12 (2016)
Attia, H., Y. Ibrahim, N., Talima, S., Elhassan, I. (2017). Second-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Single Institution Experience. Research in Oncology, 13(1), 23-27. doi: 10.21608/resoncol.2017.490.1013
Hanaa Attia; Noha Y. Ibrahim; Soha Talima; Ibrahim Elhassan. "Second-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Single Institution Experience". Research in Oncology, 13, 1, 2017, 23-27. doi: 10.21608/resoncol.2017.490.1013
Attia, H., Y. Ibrahim, N., Talima, S., Elhassan, I. (2017). 'Second-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Single Institution Experience', Research in Oncology, 13(1), pp. 23-27. doi: 10.21608/resoncol.2017.490.1013
Attia, H., Y. Ibrahim, N., Talima, S., Elhassan, I. Second-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Single Institution Experience. Research in Oncology, 2017; 13(1): 23-27. doi: 10.21608/resoncol.2017.490.1013

Second-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Single Institution Experience

Article 6, Volume 13, Issue 1, June 2017, Page 23-27  XML PDF (325.2 K)
Document Type: Original Article
DOI: 10.21608/resoncol.2017.490.1013
View on SCiNiTO View on SCiNiTO
Authors
Hanaa Attia1; Noha Y. Ibrahim email 1; Soha Talima1; Ibrahim Elhassan1, 2
1Clinical Oncology Department, Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine (NEMROCK), Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt
2Khartoum Breast Care Centre, Khartoum, Sudan
Abstract
Background: Lung cancer is the leading cause of cancer-related death worldwide. Non-small cell lung cancer (NSCLC) accounts for 80-85 %.
Methods: In this retrospective hospital based study, 424 NSCLC patients "stage IIIb-IV" were enrolled to analyze the prognostic factors and survival after receiving second-line chemotherapy.
Results: From 424 NSCLC patients, 236 (55.7%) had stage IIIb-IV disease. The majority (70%, 165/236) of these patients received best supportive care only and 30% (71/236) received first-line chemotherapy. Second-line chemotherapy was administered in 11.9% (28/236) patients after first-line chemotherapy. The median age of patients who received second-line was 58 years. The majority were males (64%). Sixty four percent had stage IV, 57% had an Eastern Cooperative Oncology Group (ECOG) performance status of 2-3, 72% had a body mass index of >18.5 kg/m2 and 57% had history of smoking. The median overall survival was 13 months (95% CI: 6.82-19.18). The first-line chemotherapy was platinum-based combination in all patients, and docetaxel was the second-line treatment in half of the patient. The most common side effects were hematological (93%) and gastrointestinal (78%). Higher risk of mortality was accompanied with age 40-60 years (HR: 5.53, 95% CI: 1.29-23.7, p = 0.022) and stage IV (HR: 3.65, 95% CI: 1.21-11.06, p = 0.022). Multivariate analysis revealed that stage IV had higher risk of mortality than stage IIIb (HR: 3.75, 95% CI 0.969-14.535, p = 0.056). The platinum-taxane combination added 3 months in the median survival (13 vs. 10 months, p = 0.4).
Conclusion: Stage IV and age between 40-60 years had a higher risk of death in NSCLC.
Keywords
Non-Small Cell Lung Cancer; advanced; Second-Line Chemotherapy
Statistics
Article View: 455
PDF Download: 587